N-乙酰天门冬氨酰谷氨酸作为一种神经递质。 - Suppr

Suppr

超能文献

NAAG as a neurotransmitter.

作者信息

Wroblewska Barbara

机构信息

Department of Biology, Georgetown University, Washington, DC, USA.

出版信息

Adv Exp Med Biol. 2006;576:317-25; discussion 361-3. doi: 10.1007/0-387-30172-0_23.

DOI:10.1007/0-387-30172-0_23

PMID:16802723

Abstract

摘要

相似文献

NAAG as a neurotransmitter.

Adv Exp Med Biol. 2006;576:317-25; discussion 361-3. doi: 10.1007/0-387-30172-0_23.

Central N-acetyl aspartylglutamate deficit: a possible pathogenesis of schizophrenia.

Med Sci Monit. 2005 Sep;11(9):HY39-45. Epub 2005 Aug 26.

[Neurotransmitters and neuropeptides in schizophrenia].

Tanpakushitsu Kakusan Koso. 1984 Dec;29(14):1838-54.

N-acetylaspartylglutamate is not demonstrated to be a selective mGlu₃receptor agonist.

J Neurochem. 2011 Dec;119(5):896-8. doi: 10.1111/j.1471-4159.2011.07480.x.

Noradrenergic hypothesis of schizophrenia.

Prog Neuropsychopharmacol Biol Psychiatry. 2005 Jun;29(5):777-8. doi: 10.1016/j.pnpbp.2005.04.003.

Probing brain chemistry.

Anal Chem. 1996 Jun 1;68(11):359A-363A.

The nagging question of the function of N-acetylaspartylglutamate.

Neurobiol Dis. 1997;4(3-4):231-8. doi: 10.1006/nbdi.1997.0153.

Expression of N-acetylaspartate and N-acetylaspartylglutamate in the nervous system.

Adv Exp Med Biol. 2006;576:7-26; discussion 361-3. doi: 10.1007/0-387-30172-0_2.

In vivo differentiation of N-acetyl aspartyl glutamate from N-acetyl aspartate at 3 Tesla.

Magn Reson Med. 2007 Jun;57(6):977-82. doi: 10.1002/mrm.21234.

Membrane phospholipid composition, alterations in neurotransmitter systems and schizophrenia.

Prog Neuropsychopharmacol Biol Psychiatry. 2005 Jul;29(6):878-88. doi: 10.1016/j.pnpbp.2005.04.034.

引用本文的文献

Parallel Metabolomics and Lipidomics of a PSMA/GCPII Deficient Mouse Model Reveal Alteration of NAAG Levels and Brain Lipid Composition.

ACS Chem Neurosci. 2024 Apr 3;15(7):1342-1355. doi: 10.1021/acschemneuro.3c00494. Epub 2024 Feb 20.

NAAG peptidase inhibitor improves motor function and reduces cognitive dysfunction in a model of TBI with secondary hypoxia.

Brain Res. 2013 Jun 17;1515:98-107. doi: 10.1016/j.brainres.2013.03.043. Epub 2013 Apr 3.

Therapeutic potential of metabotropic glutamate receptor modulators.

Curr Neuropharmacol. 2012 Mar;10(1):12-48. doi: 10.2174/157015912799362805.

NAAG peptidase inhibitor reduces cellular damage in a model of TBI with secondary hypoxia.

Brain Res. 2012 Aug 21;1469:144-52. doi: 10.1016/j.brainres.2012.06.021. Epub 2012 Jun 30.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

相似文献

NAAG as a neurotransmitter.

Adv Exp Med Biol. 2006;576:317-25; discussion 361-3. doi: 10.1007/0-387-30172-0_23.

Central N-acetyl aspartylglutamate deficit: a possible pathogenesis of schizophrenia.

Med Sci Monit. 2005 Sep;11(9):HY39-45. Epub 2005 Aug 26.

[Neurotransmitters and neuropeptides in schizophrenia].

Tanpakushitsu Kakusan Koso. 1984 Dec;29(14):1838-54.

N-acetylaspartylglutamate is not demonstrated to be a selective mGlu₃receptor agonist.

J Neurochem. 2011 Dec;119(5):896-8. doi: 10.1111/j.1471-4159.2011.07480.x.

Noradrenergic hypothesis of schizophrenia.

Prog Neuropsychopharmacol Biol Psychiatry. 2005 Jun;29(5):777-8. doi: 10.1016/j.pnpbp.2005.04.003.

Probing brain chemistry.

Anal Chem. 1996 Jun 1;68(11):359A-363A.

The nagging question of the function of N-acetylaspartylglutamate.

Neurobiol Dis. 1997;4(3-4):231-8. doi: 10.1006/nbdi.1997.0153.

Expression of N-acetylaspartate and N-acetylaspartylglutamate in the nervous system.

Adv Exp Med Biol. 2006;576:7-26; discussion 361-3. doi: 10.1007/0-387-30172-0_2.

In vivo differentiation of N-acetyl aspartyl glutamate from N-acetyl aspartate at 3 Tesla.

Magn Reson Med. 2007 Jun;57(6):977-82. doi: 10.1002/mrm.21234.

Membrane phospholipid composition, alterations in neurotransmitter systems and schizophrenia.

Prog Neuropsychopharmacol Biol Psychiatry. 2005 Jul;29(6):878-88. doi: 10.1016/j.pnpbp.2005.04.034.

引用本文的文献

Parallel Metabolomics and Lipidomics of a PSMA/GCPII Deficient Mouse Model Reveal Alteration of NAAG Levels and Brain Lipid Composition.

ACS Chem Neurosci. 2024 Apr 3;15(7):1342-1355. doi: 10.1021/acschemneuro.3c00494. Epub 2024 Feb 20.

NAAG peptidase inhibitor improves motor function and reduces cognitive dysfunction in a model of TBI with secondary hypoxia.

Brain Res. 2013 Jun 17;1515:98-107. doi: 10.1016/j.brainres.2013.03.043. Epub 2013 Apr 3.

Therapeutic potential of metabotropic glutamate receptor modulators.

Curr Neuropharmacol. 2012 Mar;10(1):12-48. doi: 10.2174/157015912799362805.

NAAG peptidase inhibitor reduces cellular damage in a model of TBI with secondary hypoxia.

Brain Res. 2012 Aug 21;1469:144-52. doi: 10.1016/j.brainres.2012.06.021. Epub 2012 Jun 30.